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in hypertrophic growth. 6, 7 Interestingly, calcineurin-NFAT signals are interwoven with various hypertrophic signaling components. It has been suggested that calcineurin-NFAT pathway is associated with stimulation of many protein kinase C isoforms and mitogen-activated protein kinase (MAPK) cascades. [8] [9] [10] KCNE2 is a member of the small auxiliary subunits of voltage-gated cation channels encoded by KCNE family gene.
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KCNE2 has the most promiscuity of function which can coassemble with multiple α-subunits of voltage-dependent cation channels, including the human Ether-á-go-go-Related Gene (hERG), KCNQ1-3, Kv3.1, Kv3.2, Kv4.2, Kv4.3, Kv1.5, and Hyperpolarization-activated, cyclic nucleotide-gated (HCN) (pacemaker), and modulate their gating, conductance, and pharmacology. [11] [12] [13] [14] [15] It is well established that KCNE2 plays an important role in maintaining the cardiac electric stability. Downregulation in KCNE2 expression has been observed in HF and linked to cardiac arrhythmia. 16 However, it remains unknown whether KCNE2 participates in structural and functional (besides electric) remodeling in diseased hearts. Our recent work demonstrated that KCNE2 modulates cardiac L-type Ca 2+ current by regulating the function of N-terminal inhibitory module of Cav1.2. 17 Furthermore, deletion or knockdown of KCNE2 decreases the magnitude of I to , 17, 18 and decreased I to can facilitate the development of cardiac hypertrophy by prolonging action potential duration and a window for Ca 2+ entry. 19 All the evidence suggests that alteration in KCNE2 may contribute to hypertrophic remodeling in diseased heart.
Hence, we examined KCNE2 expression in cardiac hypertrophy and explored the causal relationship between alteration in KCNE2 and development of cardiac hypertrophy. Our data revealed that KCNE2 expression was decreased in cardiac hypertrophy. Knockdown of KCNE2 induced cardiomyocyte hypertrophy by activation of calcineurin-NFAT and MAPK pathways. Furthermore, we found that increasing cardiac KCNE2 expression inhibited cardiac hypertrophy.
Materials and Methods

Human Heart Samples
All human studies were performed in accordance with the principles of the Declaration of Helsinki. Human heart samples were obtained via protocols approved by University of Iowa Institutional Review Boards on Human Subjects. Advanced cardiomyopathy subjects donating tissue were consented under an approved Institutional Review Board (IRB) protocol. At the time of left ventricular (LV) assist device implantation or heart transplantation, tissues were procured, flash-frozen, and stored at −80°C until use.
Animals
Animals were purchased from the Animal Center of Guangdong province (China) and handled according to a protocol approved by the Institutional Care and Use Committee of Shenzhen University that conforms to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH Publication No. 85-23, revised 1996).
Manipulating KCNE2 Expression in Cardiac Myocytes
Neonatal rat ventricular myocytes (NRVMs) were isolated from 2-day-old Sprague Dawley rats and cultured as previously described. 20 To knockdown KCNE2 expression, NRVMs were infected with recombinant adenovirus for silencing endogenous KCNE2 expression (KCNE2-shRNA short hairpin RNA, at a multiplicity of infection of 10) prepared with the BLOCK-iT Adenoviral RNA interference Expression system (Invitrogen). The sequences of the oligonucleotides for KCNE2 RNA interference were as follows: forward, CACCGGATTGGCAG CAGAAGTATAGCGAACTATACTTCTGCTGCCAATCC; reverse, AAAAGGATTGGCAGCAGAAGTATAGTTCGCTATACTTCTG CTGCCAATCC. Adenoviral vectors containing a scrambled shRNA sequence at the same multiplicity of infection served as the control (Ctrl-shRNA). To overexpress KCNE2, NRVMs were infected with recombinant Ad-KCNE2 (adenovirus vectors carrying human KCNE2 gene) at a multiplicity of infection of 5, with Ad-GFP (adenovirus carrying the gene encoding green fluorescent protein) applied at the same multiplicity of infection as the control.
Histological Analysis of Collagen Fibrosis
Mid-left ventricular short-axis heart sections were prepared and stained with Masson trichrome blue. Percentage of fibrosis was determined using ImageJ software to quantify blue (fibrotic) versus nonblue (nonfibrotic) pixels.
Immunohistochemistry
For immunofluorescence, the heart tissue sections (4 µm) were deparaffinized and rehydrated, and endogenous peroxidase was inhibited with 0.3% H 2 O 2 methanol. For antigen retrieval, slides were boiled in 0.01 mol/L, pH 6.0 sodium citrate buffer for 15 minutes in a microwave oven. After being blocked with the 5% normal goat serum, primary anti-KCNE2 polyclonal antibody (1:200; Alomone) or antiFlag polyclonal antibody (1:400, Cell signaling technology) in blocking buffer (1:50) was applied and the slides were incubated at 4°C overnight. After incubation with secondary antibody, the visualization signal was developed with 3, 3-diaminobenzidine tetrachloride.
Measurements of Cell Apoptosis
To quantify the apoptosis in transverse aortic constriction (TAC) mice heart, Terminal dexynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) assay was performed in heart tissue sections using the FragEL DNA Fragmentation Detection Kit (Calbiochem) according to the protocols of the manufacturer. To determine the percentage of apoptotic cells, TUNEL-positive and TUNEL-negative cells were counted. Results are expressed as number of TUNEL-positive cells/total cells×100%.
Animal Model of Hypertrophy With TAC
C57BL/6 male mice (9-10 weeks, 18-22 g) were randomly divided into 4 groups: sham and TAC with or without KCNE2 overexpression, 6 in each group. The TAC model was produced as described previously. 21, 22 Animals received gene therapy with doxycycline-inducible KCNE2 or empty vectors mediated by an ultrasound-microbubble technique, as described previously.
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Statistical Analysis
The data are presented as mean±SE. The Kolmogorov-Smirnov test and the Levene test were used to assess the normality of distribution and homogeneity for each variable within group. For a variable following normal distribution, the Student or Welch t test was performed when variances were equal or unequal between groups, respectively. For comparisons of multiple groups, 1-way ANOVA was performed followed by Tukey-Kramer correction. For correlated observations within animal, the general linear model (univariate) was adopted with animal as a random effect. Values of P <0.05 were considered statistically significant. All statistical analyses were performed using SPSS Statistics18.0 software (IBM Corporation, Armonk, NY).
Results
KCNE2 Protein Expression Was Decreased in Cardiac Hypertrophy
We first explored the alteration of cardiac KCNE2 expression under hypertrophic stimulation. Cardiomyocyte hypertrophy
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in vitro was produced by stimulating cultured rat ventricular myocytes (NRVMs) with phenylephrine (20 μmol/L) for 72 hours, as previously described. 22 Almost all the cells show the expression of α-actinin ( Figure I in the Data Supplement), indicating that there is little contamination of fibroblasts and other cells in the cultured NRVMs. Phenylephrine stimulation significantly increased the cell size indexed by the cell surface area and the protein levels of ANP (atrial natriuretic peptide) and β-MHC (β-myosin heavy chain), indicating successful production of cardiomyocyte hypertrophy ( Figure 1A and 1B) . Pressure overload-induced cardiac hypertrophy was produced by TAC in mice, where the expression of ANP and β-MHC was significantly increased ( Figure 1C ). We found that KCNE2 expression was significantly decreased in cardiac hypertrophy both in vitro and in vivo, where KCNE2 protein levels were decreased by 66% and 57% in phenylephrine-stimulated cells and in TAC hearts, respectively, when compared with control ( Figure 1B and 1C). Furthermore, we compared KCNE2 protein levels in human hearts from adult donors (nonfailing) and patients with idiopathic dilated cardiomyopathy and ischemic HF. The result shows that the expressions of KCNE2 in idiopathic dilated cardiomyopathy and ischemic HF are significantly lower than that in nonfailing hearts ( Figure 1D ).
Knockdown of KCNE2 Induced Cardiomyocyte Hypertrophy
We next explored whether decreased KCNE2 participates in the pathogenesis of hypertrophy by knockdown of KCNE2 expression with RNA interference in cardiomyocytes. We found that a 66% decrease in KCNE2 caused a significant increase in the expressions of both ANP and β-MHC (Figure 2A) . Meanwhile, the cell surface area of NRVMs was markedly increased ( Figure 2B ). The results indicate that decreased KCNE2 induces cardiac hypertrophy.
Increasing KCNE2 Expression Inhibited Phenylephrine-Induced Cardiomyocyte Hypertrophy
To further confirm that decreased KCNE2 contributes to the development of pathological hypertrophy, we examined the role of increasing KCNE2 expression in phenylephrine-stimulated hypertrophy. We found that increasing KCNE2 expression by 110% by transfection of cardiomyocytes with adenovirus carrying KCNE2 gene significantly inhibited phenylephrine-induced increase in cell surface area and ANP and β-MHC protein levels ( Figure 3A and 3B). The results indicate a causal relationship between downregulation of KCNE2 and pathogenesis of cardiac 
Decrease in KCNE2 Activated Ca
2+ -Dependent Calcineurin-NFAT Signaling Pathway
We next investigated the mechanisms underlying the development of hypertrophy induced by downregulation of KCNE2. Previous study indicates that knockdown of KCNE2 increased L-type Ca 2+ channel. 17 We thus examined whether Ca (Figure 4F and 4G) . The results collectively indicate that activation # P<0.05 vs KSh. C, Measurement of calcineurin (CaN) activities in 6 groups (n=5 per group). D and E, Representative Western blots (D) and quantification of nucleus and cytosolic NFAT3 protein levels (E) in 6 groups (n=5 per group). β-Actin and lamin were used as an internal control for quantification of cytosolic and nucleus NFAT3, respectively. F, Representative immunoblots and average data of ANP (atrial natriuretic peptide) and β-MHC (β-myosin heavy chain) proteins in 6 groups (n=5 per group). One-way ANOVA, Tukey HSD tests were used in C-F. *P<0.05, **P<0.01 vs CSh. -dependent calcineurin-NFAT signaling pathway contributes to decreased KCNE2-induced hypertrophy.
It has been suggested that the NFAT pathway can be regulated by Ca 2+ -independent AMP-activated protein kinase. 24, 25 We thus examined the effect of KCNE2 knockdown on AMPactivated protein kinase phosphorylation. The result shows that the phosphorylated AMP-activated protein kinase was unaffected by KCNE2 knockdown ( Figure III in the Data Supplement), indicating that the activation of calcineurin-NFAT pathway is unrelated to AMP-activated protein kinase activation.
Knockdown of KCNE2 Increased the Phosphorylation of p38, Extracellular SignalRegulated Kinase, and Jun Kinase
We also investigated whether other hypertrophy-related signaling pathways participated in KCNE2 knockdown-induced cardiomyocyte hypertrophy. Previous studies documented that hypertrophic stimuli activate kinases, such as MAPK cascades and Akt phosphatidyl inositol 3-kinase, and mediate hypertrophic responses.
26-28 Figure 5 shows that KCNE2 knockdown increased the phosphorylation levels of extracellular signal-regulated kinase (ERK), Jun kinase (JNK), and p38, but not Akt ( Figure 
Overexpression of KCNE2 Attenuated Pressure Overload-Induced Cardiac Hypertrophy
The important role of decreased KCNE2 in the development of pathological hypertrophy and the potential therapeutic effect of manipulating KCNE2 expression were further examined in a mouse model of LV hypertrophy, which was induced by pressure overload with TAC. Cardiac-specific overexpression of KCNE2 was achieved by ultrasoundmicrobubble-mediated gene transfer of the inducible KCNE2 (flag-tagged). The expression of exogenous KCNE2 was examined by immunohistochemistry detection of the flag protein in heart tissue sections. Ultrasound treatment resulted in higher levels of KCNE2 gene transfer and KCNE2 expression as demonstrated by the staining of flag protein in almost all cardiomyocytes ( Figure 6A) . Furthermore, the expression of inducible KCNE2 was detected by Western blotting of flag protein and increased level of KCNE2 protein ( Figure 6B ). At 6 and 8 weeks post-TAC, the thickness of systolic and diastolic LV posterior wall was significantly enlarged (Figure 7A through 7C). The systolic and diastolic LV internal diameter was decreased at 6 weeks but slightly increased at 8 weeks post-TAC ( Figure 7A, 7D , and 7E), suggesting that there is a compensation of cardiac function at 6 weeks but decompensation at 8 weeks after TAC. The data that LV fractional shortening and ejection fraction were significantly increased at 6 weeks post-TAC, but decreased at 8 weeks post-TAC ( Figure  V in the Data Supplement), also indicate a cardiac functional transition from compensation to decompensation. Furthermore, the heart weight/body weight ratio and the wet lung weight/body weight ratio were increased in TAC mice. Mice with KCNE2 overexpression demonstrate a blunted response to TAC (Figure 7F through 7H) . The hematoxylin and eosin staining of coronal sections of hearts shows an increase of ventricular wall thickness after TAC, which was attenuated by exogenous KCNE2 overexpression ( Figure 7I ). The protein levels of ANP and β-MHC exhibit a similar pattern in response to TAC with or without KCNE2 intervention (Figure 7J) . These results collectively indicate the contribution of KCNE2 in the pathogenesis of hypertrophy. Meanwhile, our data also suggest that increasing KCNE2 expression can also 
attenuate TAC-induced cardiac fibrosis ( Figure 7K and 7L) and myocyte apoptosis ( Figure 7M and 7N) .
Overexpression of KCNE2 Inhibited Calcineurin-NFAT and MAPK Pathways in TAC Mice
We next examined the possible involvement of calcineurin-NFAT and MAPK pathways in KCNE2-mediated attenuation of cardiac hypertrophic response. Consistent with previous studies, 26, 29, 30 calcineurin-NFAT and MAPK pathways were activated in TAC hearts, where calcineurin activity and nuclear NFAT protein content ( Figure 8A and 8B) and the phosphorylation levels of p38, ERK, and JNK were increased ( Figure 8C ). Overexpression of KCNE2 had no significant effect on calcineurin-NFAT and MAPK pathways at baseline, except that it slightly decreased the phosphorylation level of p38 in sham hearts ( Figure 8A through 8C) . However, overexpression of KCNE2 remarkably decreased calcineurin activity and nuclear NFAT protein level in TAC hearts ( Figure 8A and 8B) . Meanwhile, the phosphorylation levels of ERK, JNK, and p38 were also remarkably decreased by exogenous KCNE2 expression ( Figure 8C ).
Discussion
The major findings of this study are as follows: (1) KCNE2 expression was decreased in cardiac hypertrophy, which is a contributing factor in the development of hypertrophy; (2) overexpression of KCNE2 attenuated the development of phenylephrine-induced cardiomyocyte hypertrophy in vitro and pressure overload-induced cardiac hypertrophy in vivo; and (3) Ca 2+ -dependent calcineurin-NFAT and MAPK pathways participate in KCNE2-mediated hypertrophy. Together, these data uncover an important pathological role of KCNE2 in hypertrophic remodeling.
The pathological hypertrophic reprogramming represents a well-choreographed multiplicity of intracellular signaling pathways resulting in the hypertrophic phenotype. On hypertrophic stimuli, intracellular Ca 2+ is increased to compensate for increased wall stress and facilitates systolic performance, which consequently activates hypertrophy-related signaling pathways and thus results in the development of pathological hypertrophy. 31 In this study, we found that decreased KCNE2 induced cardiac hypertrophy by activating Ca 2+ /CaM-dependent calcineurin-NFAT signals. This was supported by the following findings: (1) knockdown of KCNE2 increased intracellular Ca 2+ transients, calcineurin activity, and NFAT translocation to nuclear; (2) blocking intracellular Ca 2+ increase with nifedipine or inhibiting calcineurin activity with FK506 attenuated the development of cardiomyocyte hypertrophy induced by knockdown of KCNE2; and (3) overexpression of KCNE2 in heart inhibited the activation of calcineurin-NFAT pathway in pressure overloadinduced hypertrophy. Our previous study reported that KCNE2 regulates L-type Ca 2+ channels by interacting with N-terminal inhibitory module of Ca v 1.2. 17 Knockdown of KCNE2 increases L-type Ca 2+ current and thus intracellular Ca 2+ level, which provides an explanation for the activation of calcineurin-NFAT pathway and consequently the development of hypertrophy.
In addition, our data suggest that a decrease in KCNE2 expression leads to activation of MAPK hypertrophic signaling pathway. It is known that 3 branches of the MAPK pathway, including MEK/ERK, JNK, or p38, seem to control distinct aspects of cardiomyocyte events. The MEK/ ERK pathway has been shown to mediate compensatory hypertrophy without pathological features. Activation of JNK and p38 is involved in cardiac myocyte apoptosis and other pathological alterations, leading to dilated cardiomyopathy and HF. Interestingly, we found that knockdown of KCNE2 activated all 3 branches of MAPK pathway, and inhibiting each cascade attenuated cardiomyocyte hypertrophy. These data indicate that KCNE2-mediated cardiac 
hypertrophy involves activation of MAPK pathway. It has been suggested that the 3 cellular signaling pathways, Ca 2+ , calcineurin, and MAPKs, share some degree commonality or interaction in the development of hypertrophy. MAPK may be activated by both α-and β-adrenergic agonists via regulation of Ca 2+ mobilization. 32 Many studies have demonstrated that calcineurin-NFAT and MAPK pathways are interdependent, though the results are somewhat contradictory. For example, De Windt et al 8 have shown that calcineurin hypertrophic signaling is associated with stimulation of JNK, but not p38 and ERK1/2, whereas Sanna et al 33 have demonstrated that calcineurin-NFAT and MEK1/ERK1/2 signaling pathways are interdependent in cardiomyocytes, in which they directly coregulate the hypertrophic growth response. Presently, we have no direct evidence to support whether activation of MAPKs by decreased KCNE2 is related to increased intracellular Ca 2+ or activation of calcineurin-NFAT or the direct effect of KCNE2 on MAPK cascades. These cellular processes might interweave and jointly contribute to KCNE2-mediated cardiac hypertrophy.
Finally, the observation that overexpression of KCNE2 attenuated the development of cardiac hypertrophy and inhibited calcineurin-NFAT and MAPK pathways provides further supporting evidence for the involvement of calcineurin-NFAT and MAPK pathways in decreased KCNE2-induced cardiac hypertrophy.
It is well established that KCNE2 plays an important role in maintaining the cardiac electric stability. Genetic mutations of KCNE2 have been linked to ventricular arrhythmia relating to long-QT syndrome. 34, 35 Previous study has demonstrated that decreased KCNE2 expression contributes to cardiac arrhythmia in infarcted cardiomyopathy in dog. 16 Cardiac hypertrophy is an independent risk for arrhythmia. We postulate that change in KCNE2 in hypertrophy predisposes the heart to arrhythmia and overexpression of KCNE2 may also have an antiarrhythmic benefit. Further experiments are warranted to testify this notion.
In summary, this study uncovered a novel pathological role of KCNE2 in cardiac hypertrophic remodeling, where cardiac KCNE2 expression was decreased by hypertrophic stimuli 
CLINICAL PERSPECTIVE
Cardiac hypertrophy is an adaptive response most commonly to hypertension. It is an independent risk factor for serious conditions, including arrhythmias, heart failure, and sudden death. Although there has been progress in understanding the mechanisms underlying the development of hypertrophy, gaps still remain, and the therapeutic strategies are limited. KCNE2 is a promiscuous auxiliary subunit of voltage-gated cation channels and plays an important role in maintaining cardiac electric stability. Our previous work has established that KCNE2 modulates cardiac L-type Ca 2+ current, suggesting its potential role in Ca 2+ -related structural and functional remodeling in diseased hearts. Here, we demonstrate that the expression of cardiac KCNE2 is decreased in phenylephrine-mediated cardiomyocyte hypertrophy and transverse aortic constriction-induced mouse cardiac hypertrophy, and in human with dilated cardiomyopathy. Knockdown of KCNE2 reproduces cardiomyocyte hypertrophy by activating Ca 2+ -dependent calcineurin-NFAT (nuclear factor of activated T cells) and mitogen-activated protein kinase signaling pathways. Particularly, adenoviral-mediated KCNE2 overexpression in cardiomyocytes suppressed phenylephrine-induced cardiomyocyte hypertrophy, and ultrasound-microbubble-mediated KCNE2 overexpression in mouse heart attenuated transverse aortic constriction-induced cardiac hypertrophy. Together these data indicate a critical role of KCNE2 in the development of cardiac hypertrophy and reinforce the therapeutic potential of targeting KCNE2 in the treatment of cardiac hypertrophy.
